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Abstract
Aims/hypothesis We quantified the effect of ADRA2A
(encoding α-2 adrenergic receptor) variants on metabolic
traits and type 2 diabetes risk, as reported in four studies.
Methods Genotype data for ADRA2A single nucleotide
polymorphisms (SNPs) rs553668 and rs10885122 were
analysed in >17,000 individuals (1,307 type 2 diabetes
cases) with regard to metabolic traits and type 2 diabetes
risk. Two studies (n=9,437), genotyped using the Human
Cardiovascular Disease BeadChip, provided 12 additional
ADRA2A SNPs.
Results Rs553668 was associated with per allele effects on
fasting glucose (0.03 mmol/l, p=0.016) and type 2 diabetes
risk (OR 1.17, 95% CI 1.04–1.31; p=0.01). No significant
association was observed with rs10885122. Of the 12
SNPs, several showed associations with metabolic traits.
Overall, after variable selection, rs553668 was associated
with type 2 diabetes risk (OR 1.38, 95% CI 1.09–1.73; p=
0.007). rs553668 (per allele difference 0.036 mmol/l, 95%
CI 0.008–0.065) and rs17186196 (per allele difference
0.066 mmol/l, 95% CI 0.017–0.115) were independently
associated with fasting glucose, and rs17186196 with
fasting insulin and HOMA of insulin resistance (4.3%, 95%
CI 0.6–8.1 and 4.9%, 95% CI 1.0–9.0, respectively, per
allele). Per-allele effects of rs491589 on systolic and diastolic
blood pressure were 1.19 mmHg (95% CI 0.43–1.95) and
0.61 mmHg (95% CI 0.11–1.10), respectively, and those of
rs36022820 on BMI 0.58 kg/m
2 (95% CI 0.15–1.02).
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Introduction
The α2-adrenergic receptor, encoded by ADRA2A gene, is a
G-coupled receptor regulating an unusually wide range of
central nervous system signalling pathways and metabolic
functions [1]. Evidence from animal studies has previously
indicated an important role for α-2 adrenergic receptor in
the cause of diabetes. Mouse models of pancreatic beta cell
overexpression of Adra2a result in glucose intolerance [2],
while Adra2a-knockout mice have enhanced insulin secre-
tion [3], implicating ADRA2A as a candidate gene for type 2
diabetes. Further evidence has arisen from studies of the
Goto–Kakizaki diabetic rat Niddm1 quantitative trait locus,
in which Adra2a was identified as the gene determining
type 2 diabetes [4].
Translating this to human studies, Rosengren et al. used
tagging single nucleotide polymorphism (SNP)s of
ADRA2A to demonstrate that a single variant (rs553668)
in the 3′ untranslated region (UTR) of the gene was
associated with modestly reduced insulin secretion and
increased type 2 diabetes risk [4]. However, this finding
could have been confounded by linkage disequilibrium
(LD) with gene variants near the ADRA2A locus. A meta-
analysis of more than 21 genome-wide association studies
(GWAS) and replication in more than 118,000 individuals
identified rs10885122 to be associated with lower fasting
glucose levels. rs10885122 is in a ‘gene desert’, 0.2 Mb
from the closest locus, ADRA2A. [5]. Although rs10885122
was also associated with reduced glucose-stimulated insulin
release [6], an association with type 2 diabetes was not
observed [5]. Thus while rs553668 was associated with
type 2 diabetes, rs10885122 was identified by association
with fasting glucose, but not with type 2 diabetes [5].
However, not all type 2 diabetes variants have been
associated with altered glucose/metabolic traits and not all
fasting glucose variants are associated with type 2 diabetes.
A second source of potential confounding may
originate from TCF7L2, encoding transcription factor
7-like 2. This gene has the strongest association with type
2 diabetes risk [7] and lies 1.8 Mb upstream of ADRA2A
and 1.6 Mb upstream of rs10885122. To evaluate whether
α-2 adrenergic receptor plays a role in type 2 diabetes and
whether it could serve as a potential therapeutic target, it is
important to investigate whether the association of the
ADRA2A loci with diabetes-related traits and type 2
diabetes risk is independent of these two other genetic
signals (rs10885122 and TCF7L2).
Our aims here were first to validate the reported
associations of ADRA2A rs553668 and rs10885122 with
metabolic phenotypes (fasting glucose, insulin, HOMA of
insulin secretion [HOMA-IR] and HOMA of beta cell
function [HOMA-B]), as well as with risk of type 2
diabetes. We did this in a meta-analysis of four prospective
studies of >17,000 individuals including 1,307 cases of
mainly prevalent type 2 diabetes. Our second aim was to
test the LD between the two SNPs, which has not been
reported before, and also the associations of these SNPs
in combination by haplotype analysis. Finally, as two of
these prospective studies (n=9,437) were genotyped using
the Human Cardiovascular Disease (CVD) BeadChip
(Illumina, San Diego, CA, USA) [8], incorporating 12
additional common ADRA2A SNPs, we investigated
whether these SNPs affect metabolic traits and type 2
diabetes risk.
Methods
Study cohorts Details of the four prospective studies,
Whitehall II Study (WHII), British Women’s Health and
Heart Study (BWHHS), the English Longitudinal Study of
Aging (ELSA) and the Northwick Park Heart Study II
(NPHSII), are presented in Table 1, with full details given
in the electronic supplementary material (ESM) Methods.
Diabetologia (2011) 54:1710–1719 1711All studies had full ethical approval and participants gave
written consent for genetic association studies.
Homoeostasis model assessment Insulin resistance esti-
mates were derived using HOMA-IR with the following
formula: HOMA-IR = fasting insulin (pmol/l) × fasting
glucose (mmol/l)/156.26. HOMA-IR data were missing for
435 (9.1%) participants. In BWHHS, HOMA was only
estimated in those without evidence of type 2 diabetes.
ADRA2A genotyping In WHII and BWHHS, genotyping
was performed using the Human CVD BeadChip (Illumina)
[8, 9]. Details of the ADRA2A SNPs used in the analysis
and of genotyping quality control in WHII and BWHHS
appear in ESM Methods.
Statistical analysis Using a pre-specified analysis plan,
each study provided homogenous model variables, which
were pooled in the meta-analysis using inverse variance
fixed effects modelling.
For continuous variables, results are presented as mean
and SD. Distribution of insulin, HOMA-IR, HDL, HbA1c
and triacylglycerol was log-transformed to give normal
distribution, but results presented are on the original scale
and therefore represent geometric means and 95% CIs for
these variables. Variables were compared in participants
with and without diabetes using Student’s t test (Table 2). A
summary weighted mean difference per allele (minor allele)
was calculated using fixed effects model by an inverse-
variance method. These results were adjusted (at the study
level) for age (all studies) and sex (WHII, ELSA), and for
recruitment centre (NPHSII). For insulin, HOMA-IR and
triacylglycerol the beta coefficients are on a log scale. For
all other variables, results are expressed in the original
units. Patients on glucose-lowering medication were ex-
cluded from the analysis of intermediate traits. Using
published data, a correction was made to the blood pressure
measures [10] of those taking anti-hypertensive medication
and triacylglycerol levels were multiplied by a factor of
1.21 (see ESM Methods) for those on lipid-lowering
medication. For rs10885122, the effect was calculated per
major (G) allele to be consistent with the Meta-Analyses of
Glucose and Insulin-Related Traits Consortium (MAGIC)
study [5]. For the other SNPs, however, the effect was
reported per minor allele. In WHII, glucose, insulin,
HOMA-IR and HOMA-B were compared using data from
all phases using multi-level mixed regression analysis
(random-intercept model), which takes into account the
intra-individual correlation between repeated measurements
and is not sensitive to missing values. These models were
fitted using the ‘xtmixed’ command in Stata (StataCorp LP,
College Station, TX, USA) and included adjustment for age
and sex. Genotypes were fitted assuming an additive
genetic model. Changes in variables between phases did
not appear to be linear, and models treating phase as a
factor were used as they explained a greater proportion of
the within-person variability than models fitting a trend
through time. We analysed type 2 diabetes status as the
outcome, by logistic regression with adjustment for age,
BMI, and where applicable for sex and recruitment centre.
For NPHSII, where diabetes cases were incident, the
diabetes effect was obtained from a Cox proportional
hazards model. In WHII a set of non-redundant ADRA2A
SNPs independently associated with diabetes was deter-
mined (variable selection) using stepwise regression based
on the Bayesian information criterion. An initial model
including age, phase and sex was fitted (for diabetes,
TCF7L2 genotype was also included). Each SNP was then
added to this baseline model and the SNP providing the
greatest reduction in the Bayesian information criterion
(BIC) was identified. This SNP was included in the base
model and the process was repeated for the remaining
SNPs. The final model was chosen when the addition of
new SNPs no longer decreased the BIC.
Haplotype analysis was performed using a maximum
likelihood model based on the stochastic-EM algorithm
Table 1 Details of study protocol for the four prospective studies used in the meta-analysis of rs553668 and rs1085122
Characteristic WHII BWHHS ELSA NPHSII
Study design Prospective cohort Prospective cohort Prospective cohort Prospective cohort
Sampling frame Workplace Across UK Respondents of HSE General practices
With DNA (n) 5,500 3,443 5,274 2,775
Genotyping method IBC 50 k CVD chip and KASPar IBC 50 k CVD chip and KASPar KASPar TaqMan
Men (%) 77 0 48 100
Follow-up (years) 20 10 10 17
Mean participant age (years) 46 69 64 56
Year of baseline survey 1985–1988 1999–2001 1998, 1999, 2001 1989–1994
HSE, Health Survey for England; KASPar, KBioscience Competitive Allele–Specific PCR genotyping system
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Paris, France) [11] (see ESM Methods).
We took p<0.01 as the level denoting evidence against
the null hypothesis of no association. To further consider
the effect of multiple testing, we calculated the false
discovery rate (FDR) for any significant results using the
Simes procedure [12].
Results
Clinical and biochemical characteristics The baseline
clinical and biochemical characteristics of the partic-
ipants in the four studies are presented in Table 2,
comparing individuals with prevalent type 2 diabetes
during the monitoring period (except for NPHSII which
included incident cases) with participants remaining free
from type 2 diabetes. Individuals with diabetes were more
likely to be obese, hypertensive and have raised total
cholesterol. In WHII and BWHHS, participants with type
2 diabetes had higher baseline fasting glucose and insulin
levels, higher HbA1c and a higher HOMA-IR index
(p<0.001 for all). In all studies, genotype distributions
were in Hardy–Weinberg equilibrium; the minor allele
frequencies for rs553668 and rs10885122 are presented in
Table 3.
Meta-analysis of rs553668 and rs10885122 for type 2
diabetes traits Measures of fasting glucose were available
in WHII, BWHHS and ELSA. Since fasting insulin
measures were only available in WHII and BWHHS, the
assessment of insulin resistance by HOMA-IR and beta cell
function by HOMA-B could only be calculated in those two
studies. In this analysis, individuals on glucose-lowering
medication were excluded. For rs553668, the minor A
allele was associated with borderline higher fasting glucose
levels than major G allele homozygotes (weighted mean
per-allele difference for fasting glucose 0.03 mmol/l, 95%
CI 0.006–0.054, p=0.016, I
2=0%, FDR p=0.12) (Fig. 1a).
This effect diminished towards the null when individuals
with prevalent diabetes were excluded or analysis was only
performed in those with prevalent diabetes (data not
shown), this diminution being at least in part because of
loss of power. For rs553668, the pooled weighted mean
per-allele difference estimates for the following traits were:
fasting insulin 1.2% (95% CI −0.016, 4.0; p=0.40);
HOMA-IR 1.8% (95% CI −1.1, 4.8; p=0.22) and HOMA-
B −0.97% (95% CI −5.52, 3.59; p=0.68; Fig. 1b–d). There
was a trend towards an increase in systolic blood pressure
with per allele difference 0.43 (95% CI −0.14, 1.00);
however there was considerable heterogeneity between
studies (I
2 71.8% and 58.7% for systolic and diastolic BP
respectively) (Fig. 1e, f). Rs10885122 was not associated
with fasting glucose, insulin, HOMA-IR, HOMA-B or blood
pressure (Fig. 1a–f).
Meta-analysis of rs553668 and rs10885122 for type 2
diabetes risk Pooling data from the four studies yielded a
summary OR for rs553668 with type 2 diabetes of 1.17
(95% CI 1.04–1.31; p=0.01, FDR p=0.11; Fig. 2). A
sensitivity analysis using a recessive model and restricting
to individuals with low BMI did not alter this and the OR
increased to 1.34 (95% CI 0.96–1.86), but did not reach
significance (p=0.08). No association was observed be-
tween rs10885122 and type 2 diabetes risk (OR 0.93, 95%
CI 0.81–1.06; p=0.27) (Fig. 2).
Haplotype analysis of rs553668G>A and rs10885122G>T We
examined the haplotypic effect of the two SNPs on type 2
diabetes traits by meta-analysis across the four studies
(ESM Table 1). The results for fasting glucose and type 2
diabetes are presented in Fig. 3a, b. Compared with the
common haplotypes rs553668G/rs10885122G (frequency
0.72), haplotypes rs553668A/rs10885122G (frequency
0.16) and rs553668G/rs10885122T (frequency 0.11)
showed no effect on fasting glucose, while haplotype
rs553668G/rs10885122T was associated with lower fasting
glucose (p=0.006, FDR p=0.06). However, the very rare
haplotype carrying both minor alleles rs553668A/
rs10885122T (frequency 0.007) was associated with higher
fasting glucose (p<0.00001, FDR p<0.00001). Permutation
analysis yielded a p value of 0.068 with a standard error of
0.091, suggesting this was not robust. For type 2 diabetes
risk, the haplotypes with the minor allele of rs553668 and
major allele of rs10885122 (rs553668A/rs10885122G)
showed a trend to association with type 2 diabetes risk
(OR 1.16, p=0.03, FDR p=0.2). No haplotype showed
association with the other type 2 diabetes traits (ESM
Fig. 1a–e).
Association of ADRA2A SNPs with metabolic traits Nine-
teen SNPs in the intronless coding region of ADRA2A or in
flanking regions of the gene were on the Human CVD
BeadChip, which was used to genotype participants in
WHII and BWHHS. Of these, five SNPs were monomor-
phic and one occurred at a very low frequency; these were
excluded. The LD pattern and minor allele frequency of the
SNPs in WHII are shown in ESM Fig. 2a, b and ESM
Table 2, respectively. The meta-analysis of the association
of these 13 SNPs and rs1088522 with intermediate traits in
WHII and BWHHS are presented as a heat plot (Fig. 4,
ESM Fig. 3a–g). In addition to the associations of rs553668
reported above, several SNPs showed association with the
traits. Thus rs17186196 and rs7096359 demonstrated
strong per-allele raising effect for fasting glucose,
1714 Diabetologia (2011) 54:1710–1719HOMA-IR, systolic BP and BMI (p<0.03 for all), while
rs491589 showed strong consistent association with higher
fasting glucose, and systolic and diastolic BP (p<0.01 for
all). For FDR corresponding to the p values in the heat
plots, see Fig. 4.
Identification of independently associated SNPs in
WHII We used a variable selection model with the
trait-associated ADRA2A variants to identify which of the
ADRA2A SNPs were independently associated with these
metabolic traits in WHII (Table 4). For fasting glucose,
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SNP
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Fig. 1 Meta-analysis of fasting glucose (a), fasting insulin (b),
HOMA-IR (c), HOMA-B (d), systolic BP (e), and (f) diastolic BP.
Panels show the weighted mean differences (diff) adjusted for age (all
studies) and sex (WHII, ELSA) in WHII, BWHHS, ELSA and
NPHSII for rs553668 and rs10885122
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2=0.01) remained in the
model. For systolic BP, rs491589, which was in strong
LD with rs553668 (R
2=0.94), remained in the model after
adjustment for the lead SNP (rs553668). The only SNP
that was independently associated with BMI was
rs36022820, which showed no LD with rs553668 (R
2=
0.0). In the stepwise analysis for type 2 diabetes,
rs553668 alone was independently associated with type
2 diabetes risk (OR 1.38, 95% CI 1.09–1.73; p=0.007).
However, the OR was attenuated (OR 1.33, 95% CI 0.98–
1.80; p=0.07) when adjustment was made for clinical risk
factors (age, triacylglycerol, insulin, and systolic and
diastolic BP). None of the haplotypes from the combined
SNP analyses reached statistical significance (data not
shown). Since TCF7L2, the gene most strongly associated
with type 2 diabetes risk, lies 1.8 Mb upstream of
ADRA2A on chromosome 10, we forced TCF7L2
rs7903146 into the stepwise models, but it did not
attenuate the association observed with rs553668, pro-
viding evidence of independent associations with type 2
diabetes risk (ESM Table 3).
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Fig. 2 Meta-analysis of type 2 diabetes (T2D) risk using data from
WHII, BWHHS, ELSA and NPHSII for rs553668 and rs10885122
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Fig. 3 Meta-analysis of haplotypes of rs553668G>A/rs10885122G>T using data from WHII, BWHHS, ELSA and NPHSII for (a) fasting
glucose and (b) type 2 diabetes (T2D)
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This paper takes forward our present knowledge of the role
of ADRA2A in type 2 diabetes. It builds on the data
provided by the pooled GWAS analysis, which identified
ADRA2A (with the lead SNP rs10885122, 0.2 MB from the
gene) as a gene determining fasting glucose levels, but not
type 2 diabetes, as well as on the study by Rosengren (with
the lead SNP rs553668 in the 3′UTR) [4], which reported
an association with insulin secretion and type 2 diabetes
risk. We have examined the combined effects of these
two SNPs and report the lack of LD between them, thus
suggesting independent effects. We have also examined
the impact of additional variants within the gene, shown a
novel association between ADRA2A variants and compo-
nents of the metabolic syndrome (excluding participants on
glucose-lowering medication), and confirmed the association
with type 2 diabetes risk. Although our data did not allow for
replication of the effect on insulin secretion, in meta-analysis
we report a borderline association for fasting glucose levels
(p≤0.016), which considering the size of our study suggests
that this effect is not as strong as that on insulin secretion
reported by Rosengren et al. [4].
Confirming the effect of rs553668 on fasting glucose levels
and type 2 diabetes risk Our first aim was to examine the
independent effects of the two previously reported
ADRA2A SNPs rs553668 [4] and rs10885122 [5]o n
fasting glucose. In our UK-based studies (totalling
>17,000 individuals, with fasting glucose measures in
~12,300 individuals), we identified a borderline significant
association between rs553668 and fasting glucose meas-
ures, with each minor allele being associated with a mean
increase of 0.030 mmol/l (95% CI 0.006–0.054; p=0.016).
We were not able to replicate the association of
rs10885122 with fasting glucose levels as reported in the
global analysis for the MAGIC study (per-allele effect of
the major allele 0.022 mmol/l [±0.004]) [5], despite the
fact that WHII and BWHHS contributed to that study. The
MAGIC study comprised over 118,000 individuals and the
small per-allele difference we report suggests that our
study was underpowered to confirm this effect. Consistent
with its association with fasting glucose, rs553668 was
also associated with an increased risk of type 2 diabetes in
our study (per-allele OR 1.17; 95% CI 1.04–1.31; p=
0.01). The OR reported in the MAGIC study for a
recessive effect on type 2 diabetes risk of 1.42 (95% CI
1.01–1.99; p=0.04) [4] overlaps with recessive effect in
our study (OR 0.93; 95% CI 0.81–1.06). The smaller
effect we observed may reflect the difference between the
case–control comparison (recessive model) used in the
MAGIC study, vs our prospective analysis (additive
model).
We extended our analysis of the above two SNPs, in
individuals not on glucose-lowering medication, and found
that in addition to an association of rs553668 with glucose
and type 2 diabetes risk, this SNP was also associated with
a trend towards higher fasting insulin and HOMA-IR,
consistent with a deleterious metabolic milieu.
Combined effects of rs553668 and rs10885122 in haplotype
analysis Although, in combined SNP analysis, the
haplotype-bearing minor alleles of rs553668 and
rs10885122 (haplotype AT) were very infrequent (0.7%),
this haplotype was associated through meta-analysis with
an approximately 0.45 mmol/l higher fasting glucose level
(p<6×10
−18 for two copies) than the common haplotype
(Fig. 3a). Since rs553668A is associated with higher fasting
glucose and the rs10885122T minor allele with lower
fasting glucose [5], this unexpected finding will require
confirmation by further studies. It is possible that this rare
haplotype tags an untyped rare variant.
Other ADRA2A variants and features of the metabolic
syndrome Rosengren et al. used a tagging SNP approach
and identified 19 ADRA2A SNPs for analysis with glucose
and insulin traits, and type 2 diabetes risk [4] in a relatively
small study of 935 well characterised individuals. However,
only rs553668 showed consistent association with insulin
secretion. In comparison, our analysis examined the
association of 13 ADRA2A SNPs in the Human CVD
BeadChip (we additionally included rs10885122) with a
range of phenotypes available in WHII and BWHHS
(approximately 9000 participants). Only rs553668 was
shared between our study and that of Rosengren et al.,
and for the remaining SNPs there was little or no LD. In our
meta-analysis of participants not on glucose-lowering
medication in WHII and BWHHS, several SNPs showed
association with fasting glucose, HOMA-IR, systolic and
diastolic blood pressure, and BMI. In WHII, 2 h insulin
measures after OGTT were available, but we did not
observe an association with any of the ADRA2A SNPs
(data not shown).
Biological plausibility of ADRA2A and type 2 diabetes The
biological plausibility of the observed association between
rs553668 and diabetes risk arises from studies of the
diabetic Goto–Kakizaki rat. The narrowing down of the
Niddm1 susceptibility locus to Adra2a was confirmed by
the finding that signalling through the α-2 adrenergic
receptor reduced the number of insulin vesicles that dock
at the membrane, limiting insulin secretion [4]. Studies of
ADRA2A expression in human pancreatic beta cells
demonstrated that carriers of rs553668A have reduced
insulin secretion and higher mRNA expression. Overpro-
duction of α-2 adrenergic receptor could explain the
Diabetologia (2011) 54:1710–1719 1717increased type 2 diabetes risk and suggests its use as a
potential therapeutic target.
A previously reported analysis of ADRA2A suggested
that functional variants occur in the promoter, 5′UTR or 3′
UTR of the gene, and not in the coding sequence of this
intronless gene, supporting control at the level of expres-
sion [13]. Rs553668 is in the 3′UTR of ADRA2A, and the
minor A allele is reported to be associated with over-
expression of the gene [4]. This may be a result of disrupted
degradation of mRNA signal by the base change encoded
by this SNP [14].
Identification of independently acting ADRA2A SNPs and
allelic heterogeneity Variable selection carried out in WHII
identified both rs553668 and rs17128356 as showing
association with glucose, suggesting more than one
functional variant.
Several studies have examined the association between
ADRA2A variants and obesity, but those results have been
conflicting, probably due to study design [15] and small
sample size [16]. We report here that several SNPs showed
robust association with BMI, although only rs36022820,
which had no LD with rs553668, remained in the model
after variable selection. The mechanism, however, is
unclear.
ADRA2A SNPs and blood pressure We did not see a strong
association between rs553668 and BP in our pooled
analysis; however, the variant that remained in the model
with systolic BP after variable selection was rs491589,
which shows strong LD with rs553668. Rosengren et al.
reported [4] that while showing an association with adverse
lower insulin secretion, rs553668Awas also associated with
lower diastolic BP. In our study the minor allele rs491589G
was associated with higher systolic BP and a trend towards
higher fasting glucose levels. However, the fact that
rs491589, which is probably a non-functional variant, is
associated with BP after adjustment for the lead SNP
(rs553668) suggests it may mark a third (unidentified)
variant, which may be responsible for the association. Two
other studies have reported higher stress-induced BP
associated with rs553668A [13, 14].
Together all these associations suggest that more than
one functional SNP in ADRA2A may affect components of
the metabolic syndrome, but these data need further
replication.
Translational implication of ADRA2A inhibition Despite
the fact that the association with blood pressure needs
further confirmation, this is of interest since α-2 adrenergic
receptor is the target molecule for the centrally acting α-2
adrenergicreceptoragonist,clonidine,whichisusedtoreduce
blood pressure [17]. In a recent GWAS of platelet aggrega-
tion in response to agonists, rs4311994, which is ~62 kb
upstream of ADRA2A, was identified as one of the seven loci
associated with this trait, in this case specifically with
response to adrenaline (epinephrine) [18]. Thus the α-2
adrenergic receptor represents a feasible drug target for
several disease-related phenotypes.
Evidence from this study, supporting previously pub-
lished data [4, 5], reinforces the notion that the α-2
adrenergic receptor pathway should be considered as a
potential drug target for prevention of type 2 diabetes.
However, an α-2 adrenergic receptor antagonist, which
might promote insulin secretion and lipolysis, could
potentially raise blood pressure; thus, a drug that did not
cross the blood–brain barrier might be required.
Study limitations Some of the primary results in this paper
are effectively derived through sub-analyses of published
data [5], which could be a limitation. However, we feel that
the inclusion of these data has taken work on ADRA2A
variants forward. With the four studies presented here, it
was not possible to estimate the between-study variance
Table 4 Results of the variable selection of ADRA2A SNPs with intermediate traits in WHII, showing SNPs that remained in the model
SNP Fasting glucose (mmol/l) Systolic BP (mmHg) BMI (kg/m
2) OR T2D
rs553668 0.036 (0.008–0.065) 1.38 (1.09–1.73)
p value 0.011 0.007
rs491589 1.19 (0.43–1.95)
p value 0.002
rs36022820 0.58 (0.15–1.02)
p value 0.009
rs17128356 0.066 (0.017–0.115)
p value 0.008
Per-allele associations are given as OR (95% CI)
Excludes results of participants on glucose-lowering medication and corrected for anti-hypertensive use
T2D, type 2 diabetes
1718 Diabetologia (2011) 54:1710–1719reliably and so fixed effects models were used, an approach
that assumes that the results are unaffected by differences in
the study populations. Although multiple testing was
performed, many phenotypes were highly correlated and
therefore we chose a liberal p value cut-off of p<0.01.
However, the FDRs were also calculated for all associations
showing statically significant results, thus taking into account
multiple testing. Due to the large number of tests performed,
almost all results would be non-significant if conservative
adjustments for multiple testing were applied. A further
potential limitation is the confounding of genotype effects
on diabetes and metabolic traits by the inclusion of partic-
ipants taking glucose-lowering, blood pressure-lowering or
lipid-lowering medications. However, the associations
reported here were robust when such individuals were
excluded, or when the lowering effects of medication were
adjusted upwards using published correction factors.
Conclusions Our results confirm the association of
ADRA2A with type 2 diabetes risk phenotypes and risk.
We also identified variants in the gene that are associated
with blood pressure and BMI. This study suggests that the
α-2 adrenergic receptor could be a therapeutic target, but
further research on downstream pathways will be necessary,
before it can be targeted.
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